Clinical trials: Recurrent GBM
Malignant Glioma, Recurrent Ependymoma
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in…
- Trial name
- NCT00634231
- Testing
- AdV-tk, valacyclovir, Radiation
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Candel Therapeutics, Inc.
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
This phase I/II trial is studying the side effects and best dose of erlotinib, tipifarnib, and temsirolimus when given together with sorafenib and to see how well they work in treating patients with recurrent glioblastoma…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00335764
- Testing
- sorafenib tosylate, erlotinib hydrochloride, tipifarnib
- Where
- 7 sites in United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
The purpose of this study is to estimate the capacity of the multimodal imaging parameters measured at 15 days and 2 months of initiation of treatment with bevacizumab, to measure changes in clinical status (sensitivity to…
- Trial name
- IMAGLIO (NCT02841332)
- Testing
- F-MISO, Cerebral magnetic resonance imagery, Bevacizumab
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Toulouse
Glioblastoma Multiforme
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.
- Trial name
- NCT04765098
- Testing
- Tamoxifen, Etoposide
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- AHS Cancer Control Alberta
Brain and Central Nervous System Tumors
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma…
- Trial name
- NCT00003293
- Testing
- leflunomide, procarbazine hydrochloride
- Where
- 35 sites in United States, Canada
- Sponsor
- Pfizer
Glioblastoma, Recurrent Glioblastoma
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Evaluate safety and tolerability of ibudilast (MN-166) and TMZ combination treatment for 1 cycle (28…
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM, Newly Diagnosed Glioblastoma
- Trial name
- NCT03782415
- Testing
- MN-166, Temozolomide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- MediciNova
Recurrent Glioblastoma
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the…
- Trial name
- CheckMate 143 (NCT02017717)
- Testing
- Nivolumab, Bevacizumab, Ipilimumab
- Where
- 112 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354068
- Testing
- imatinib mesylate, temozolomide, pharmacological study
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Duke University
Malignant Glioma, Glioblastoma Multiforme
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00683761
- Testing
- 131I-TM601
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- TransMolecular
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm
- Trial name
- NCT01122888
- Testing
- Cilengitide, Clinical Observation, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
A prospective, open label, single-center, early feasibility trial will be conducted to assess the safety and feasibility of a home-based Static Magnetic and Electric (sBE) device applied for 8 hours/day during sleep in adult…
- Trial name
- NCT05410301
- Testing
- Static Magnetic and Electric (sBE) device, Lomustine, Bevacizumab
- Where
- United States
- Sponsor
- Varun Monga, MD
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Glioblastoma
Tivozanib for Recurrent Glioblastoma
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01846871
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Primary objective - to determine the 6-month progression free survival (PFS) of adult patients with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus (Avastin) bevacizumab.
- Trial name
- NCT00883298
- Testing
- temozolomide and bevacizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Center for Neurosciences, Tucson
Recurrent Glioblastoma
Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).
- Trial name
- NCT00250887
- Testing
- Gefitnib
- Where
- Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of Pembrolizumab and M032 (NSC 733972)
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety and tolerability of Pembrolizumab when given in conjunction with M032, an Oncolytic Herpes Simplex Virus (oHSV) that expresses IL-12 and…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
- Trial name
- NCT05084430
- Testing
- M032, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Brain and Central Nervous System Tumors
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
RATIONALE: Thalidomide may stop the growth of malignant glioma by stopping blood flow to the tumor. Drugs used in chemotherapy, such as procarbazine, work in different ways to stop tumor cells from dividing so they stop growing…
- Trial name
- NCT00079092
- Testing
- procarbazine hydrochloride, thalidomide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Glioblastoma Multiforme, Glioblastoma
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, GBM
- Trial name
- NCT02663271
- Testing
- Bevacizumab, Optune, Brain MRI
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Glioblastoma Multiforme, Glioblastoma
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
New treatments are greatly needed for patients with recurrent glioblastoma. Metronomic temozolomide is a standard treatment option but has, at best, modest activity.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, GBM
- Trial name
- 329 (NCT03119064)
- Testing
- Nanoliposomal Irinotecan, Temozolomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brown University